SSY Group Limited — Capital/Financing Update 2012

May 3, 2012

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [283 x 113] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

GRANT OF OPTIONS

The board of Directors (the “ Board ”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “ Company ”) announces that, subject to acceptance by the grantees, a total of 40,000,000 Options have been granted pursuant to the Share Option Scheme. According to Rule 17.06A of the Listing Rules, details of the grant of Options are set out as follows:–

1. Date of grant: 3 May 2012

2. Exercise price of Options granted: HK$1.78

3. Number of Options granted: 40,000,000

4. Closing price of Share on date of grant: HK$1.78

5. Validity period of Options:

Three years from date of Options granted, i.e. from 3 May 2012 to 2 May 2015

1. All Options are granted to the Directors of the Company with details as follows:–

Name of grantees	Position in the Company	Number of Options
Mr. Wu Qin	Chairman	20,000,000
Mr. Qu Jiguang	Executive Director	20,000,000

1

DEFINITIONS

“Option(s)”

option(s) to subscribe for Shares granted pursuant to the Share Option Scheme and each Option shall entitle the holder of the Option to subscribe for one Share;

“Share(s)”

ordinary share(s) of par value of HK$0.02 each in the share capital of the Company; and

“Share Option Scheme”

share option scheme adopted by a written resolution of all shareholders of the Company on 16 October 2005.

By order of the Board Chow Hing Yeung Company Secretary

Hong Kong, 3 May 2012

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Huang Chao, Mr. Wang Xianjun, Mr. Duan Wei, Mr. Bao Leyuan and Ms. Gao Shuping as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

2